News | March 09, 2010

Thallium Imaging Offers Alternative During Isotope Shortage

Dual-isotope imaging: reduced-dose, shorter-scan-time stress images acquired with 20 mCi Tc-99m at 10 sec/frame. Photo courtesy of Mayo Clinic.

Dual-isotope imaging: reduced-dose, shorter-scan-time rest images acquired with 2mCi Tl-201 at 20 sec/frame. Photo courtesy of Mayo Clinic.

March 9, 2010 – As an alternative to the technetium (Tc-99M) isotope used in many nuclear imaging studies, UltraSPECT is advocating the use of thallium isotope (TI-201) imaging as an alternative. Due to the impact of the Canadian reactor shutdown combined with the recently announced six-month repair plan of the Dutch reactor, the global shortage of Tc-99m is expected to remain grave in the next few months, leaving nuclear medicine in a precarious position. The shortage means there is an inability to provide patients with needed tests, longer delays in exam scheduling, use of reduced-dose imaging protocols, and loss of business to other imaging modalities such as CTA, echo and cardiac PET. The company offers two cardiac products, Xpress.Cardiac and Xpert3.Cardiac, which support Tl-201 imaging. These products utilize UltraSPECT's proprietary WBR image reconstruction capabilities to enable reduced-dose and enhanced-resolution thallium imaging. The products allow the utilization of lower dose imaging protocols using Tc-99m with no compromise in terms of imaging acquisition times and diagnostic value. They also support reduced-dose and enhanced-resolution Tl-201 imaging, helping alleviating the impact of the technetium shortage while reducing patient radiation exposure. UltraSPECT products feature connectivity to the imaging systems of all three major nuclear medicine camera manufacturers. “UltraSPECT has allowed us to acquire high-quality gated SPECT images with Tl-201, without increasing scan times,” said John Zeitz, M.D., chief of nuclear medicine at Beaumont Hospital in Troy, Mich. “Previously, we would have to increase our imaging time by 50 percent in order to achieve decent image quality for the gated cine reconstruction." The one-day dual-isotope (Tl-201 and Tc-99m) protocol performed with the Xpress3.Cardiac combines reduced doses with shorter scan times. Reduced-dose, shorter-scan-time rest Tl-201 imaging is followed by reduced-dose, shorter-scan-time Tc-99m stress imaging, rendering the procedure safer and more comfortable for the patient, while ensuring sustained/increased patient throughput for the practice: • Rest: Tl-201, 2 mCi (female) / 3 mCi (male); 20sec. per stop. • Stress: Tc-99m, 20 mCi (female) / 30 mCi (male); 10sec. per stop. UltraSPECT’s Xpress.Cardiac, Xpress3.Cardiac, and Xpress/Xact.BoneTM products are distributed in the USA exclusively by Cardinal Health. UltraSPECT products are distributed in the USA by Cardinal Health (www.cardinalhealth.com). For more information: www.ultraspect.com

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init